Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

591.04 -0.82 (-0.14%)
Official Closing Price Updated: 4:10 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Check Out What Whales Are Doing With LLY
Via Benzinga
Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?
The answer is relatively clear. 
Via The Motley Fool
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
Lilly's Mounjaro is gaining ground on Novo Nordisk's Ozempic. 
Via The Motley Fool
Eli Lilly (LLY) Q3 2023 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Treasuries, Stocks Extend Gains Following Fed Meeting As Apple, Jobs Report Loom
(Thursday market open) The World Series is over, but Wall Street remains in the thick of this week’s triple play of a Fed meeting, Apple (NASDAQ: AAPL) earnings and Friday’s October jobs report. So... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Eli Lilly Stock Is Jumping Today
Investors liked the drugmaker's Q3 update. 
Via The Motley Fool
Eli Lilly Smashes Third-Quarter Forecasts As Diabetes Blockbuster Grows 652%
Mounjaro helped drive a third-quarter beat, growing sevenfold. 
Via Investor's Business Daily
This Is What Whales Are Betting On Eli Lilly
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Some Surprise Names Led The S&P 500 In October
The best and worst stock performers in the S&P 500 for October include some surprising names. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Weight Loss Drugs Drove Eli Lilly's Massive Profit - But They Still Cut Their Annual Profit Guidance, Here's Why
Eli Lilly And Co (NYSE: LLY) has reported Q3 sales of $9.49 billion, up 37% Y/Y, beating the consensus of $8.95 billion, dr 
Via Benzinga
Weight Watchers Q3 Earnings Preview: Will Ozempic Weigh Down WW Stock?
Weight Watchers stock, trading as WW, is already down 30% YTD. Here's what analysts will be watching in the Q3 earnings report. 
Via Benzinga
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. 
Via Benzinga
Topics Economy
Exposures Interest Rates
7 A-Rated Tech Stocks to Buy for November
By investing in tech stocks, investors can capitalize on groundbreaking technological advancements and be a part of the future. 
Via InvestorPlace
Fear Continues To Grip Markets After Fed's Rate Decision
The CNN Money Fear and Greed index remained in the "Fear" zone on Wednesday. U.S. stocks closed higher on Wednesday after the Federal Reserve maintained interest rates for a second straight time. Bond... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals
McKesson earnings are on tap, with Cencora and Cardinal Health due soon. 
Via Investor's Business Daily
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
7 A-Rated Stocks to Buy in Q4
This is one of the best times of the year to look for stocks to buy, as the market historically shows an increase 80% of the time in Q4. 
Via InvestorPlace
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology. 
Via The Motley Fool
Ozempic Supply Is Running Low: Here's Why That Can Be A Problem
Ozempic, the diabetes drug also used as a so-called "miracle" weight-loss drug, has been sweeping through America and is now in limited supply. 
Via Benzinga
AI-Powered Investing: 3 Promising Stocks for 2024
With the further commoditization of asset management, stock predictions by AI have become far more prevalent. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Five Hot Earnings Charts
Each one of these five companies has beat the performance of the S&P 500 year-to-date. And they have amazing earnings surprise track records, including one that has a 5-year perfect record. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Verve Stock Soars On $250 Million Eli Lilly Deal
Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Eli Lilly Stock Has Quadrupled in 3 Years. Could a Weight-Loss Drug Approval Make It Happen Again?
Mounjaro may be a winner, but all its upside is already priced in. An approval poses the risk of profit-taking. 
Via The Motley Fool
Why Beam Therapeutics Stock Is Getting Bought Today
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's  
Via Benzinga
Benzinga Bulls And Bears: Tesla, Chevron, Eli Lilly And Dogecoin Co-founder's 3 Favorite Cryptos
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
The three companies are spending big on IBD therapies. 
Via The Motley Fool
Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets
It has been another week of volatility in the stock market, characterized by mounting fears of a wider Middle East conflict and a more cautious fourth-quarter earnings outlook announced by U.S.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.